Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier (Servier) announced that they have entered into a worldwide ex-U.S. and Japan agreement for the discovery and development of novel TGR5 agonists for the treatment of type 2 diabetes and other metabolic indications. The...